Trovafloxacin

PURPOSE: Gemifloxacin (GEM) is a potent fluoroquinolone with excellent activity against respiratory tract infection (RTI) pathogens, including S. pneumoniae (SP). Pooled data from 17 phase III clinical trials for GEM with community-acquired pneumonia, acute bacterial sinusitis & acute exacerbation of chronic bronchitis patients (pts.

METHODS: 530 Pts where SP was the sole pathogen & SP susceptibility known, were evaluated. Clinical success at end of therapy (EOT) & at follow-up (FU, approx. 1-3 weeks after treatment) was studied. Main comparators (CMP) were cefuroxime (61 pts), amoxicillin-clavulanate (37 pts), trovafloxacin (34 pts), cefuroxime & clarithromycin (28 pts), levofloxacin or clarithromycin (11 pts). Percentage success based on susceptibility to penicillin G (Pen) and/or macro[ides (Mac) is shown (Table, S = susceptible, NS = non-susceptible, R = resistant, N = pts/group).

RESULTS: See Table.

CONCLUSION: GEM showed good clinical success against all resistance phenotypes. These data support the use of GEM in the treatment of RTI, especially where MacR SP prevails.

CLINICAL IMPLICATIONS: The emergence of antibacterial resistance may effect empirical therapy, gemifloxacin has been shown to be effective against resistant phenotypes of th emost common bacterial respiratory pathogen.

DISCLOSURE: Thomas File, Consultant fee, speaker bureau, advisory committee, etc. TF & LM are consultants to Oscient.

Ian Morrissey PhD Thomas File MD * Lionel Mandell MD Glenn S. Tillotson MS SUMMA Healthcare, Akron, OH

COPYRIGHT 2005 American College of Chest Physicians
COPYRIGHT 2005 Gale Group